Clincosm LogoSign in Get a demo

Mediastinal Grey Zone Lymphoma From the LYSA

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT03037177
Collaborator
(none)
99
Enrollment
1
Location
41
Duration (Months)
2.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. Investigators report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    99 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    Mediastinal Grey Zone Lymphoma: Clinico-pathological Characteristics and Outcomes of 99 Patients From the LYSA
    Study Start Date :
    Jan 1, 2013
    Actual Primary Completion Date :
    Jan 1, 2016
    Actual Study Completion Date :
    Jun 1, 2016

    Arms and Interventions

    Arm Intervention/Treatment
    CHL like GZL

    Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
    PMBCL like GZL

    Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
    Composite

    with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy

    Outcome Measures

    Primary Outcome Measures

    1. EFS in the global population of GZL [EFS: Event Free Survival from date of randomization until the date of first documented progression, up to 130 months]

      Event-free survival (EFS) was calculated from the date of diagnosis to the date of progression, a change of therapy that was not initially scheduled (radiotherapy, high-dose therapy with autologous stem cell transplantation and other unplanned treatments) or death from any cause.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • cases with an intermediate morphology and phenotype between CHL and PMBCL were included after central pathological review
    Exclusion Criteria:

    • Cases of CHL with partial CD20 expression or low expression in tumoral cells were excluded and considered as CD20-positive CHL

    • Exclusion of sequential form patients (with a diagnostic biopsy of PMBCL and a relapse biopsy of CHL or vise-versa) as they represent a biases for statistical analysis.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre hospitalier Lyon sud Pierre Bénite Rhône Alpes France 69126

    Sponsors and Collaborators

    • Hospices Civils de Lyon

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hospices Civils de Lyon
    ClinicalTrials.gov Identifier:
    NCT03037177
    Other Study ID Numbers:
    • 69HCL16_0721
    First Posted:
    Jan 31, 2017
    Last Update Posted:
    Jan 31, 2017
    Last Verified:
    Oct 1, 2016
    Additional relevant MeSH terms:
    Lymphoma

    Study Results

    No Results Posted as of Jan 31, 2017